Timelines for successful endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: what are we aiming for?

Endoscopy 2022; 54(10): 934-935
DOI: 10.1055/a-1904-7988

Editorial

Referring to Mittal C et al. p. 927–933

Rehan Haidry

¹Gastroenterology, University College London Medical School, London, United Kingdom

References
1 Mittal C, Muthusamy VR, Simon VC. et al. Threshold evaluation for optimal number of endoscopic treatment sessions to achieve complete eradication of Barrett’s metaplasia. Endoscopy 2022; 54: 927-933
2 Haidry RJ, Dunn JM, Butt MA. et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013; 145: 87-95
3 Phoa KN, Pouw RE, Bisschops R. et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut 2016; 65: 555-562
4 Shaheen NJ, Sharma P, Overholt BF. et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009; 360: 2277-2288
5 Wani S, Muthusamy VR, Shaheen NJ. et al. Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium. Gastrointest Endosc 2017; 86: 1-17
6 van Munster SN, Frederiks CN, Nieuwenhuis EA. et al. Incidence and outcomes of poor healing and poor squamous regeneration after radiofrequency ablation therapy for early Barrett’s neoplasia. Endoscopy 2022; 54: 229-240